Teprotumumab
- Generic Name
- Teprotumumab
- Brand Names
- Tepezza
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1036734-93-6
- Unique Ingredient Identifier
- Y64GQ0KC0A
- Background
Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016 and was approved by the FDA in January 2020 for the treatment ...
- Indication
Teprotumumab is indicated for the treatment of thyroid eye disease regardless of disease activity or duration.
- Associated Conditions
- Thyroid Eye Disease
- Associated Therapies
- -
Viridian Therapeutics' stock jumps after Phase III trial met all endpoints
Viridian Therapeutics' veligrotug met all primary and secondary endpoints in Phase III THRIVE trial for thyroid eye disease (TED), showing significant improvements in signs and symptoms. The treatment group had a 70% proptosis responder rate and 54% complete resolution of diplopia, compared to 5% and 12% in the placebo group, respectively. Veligrotug was generally well-tolerated, with no treatment-related serious adverse events. The company's stock price rose by 32% following the announcement.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath